Abstract: NR4A1 ligands, pharmaceutical compositions including the NR4A1 ligands, and related methods of use are described. Methods of treating a disease or condition in an individual treatable by modulation of NR4A1 activity, comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition described herein.

Abstract: Methods of treating endometriosis through modulation of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) activity including administration of an NR4A1 ligand to an individual in need thereof are described. In an embodiment, the compounds include methylene substituted diindolylmethanes.

Abstract: NR4A1 ligands, pharmaceutical compositions including the NR4A1 ligands, and related methods of use are described. Methods of treating a disease or condition in an individual treatable by modulation of NR4A1 activity, comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition described herein.

Abstract: In an embodiment, the present disclosure pertains to a method of treating a disease by induction of activity in cells. Generally, the method includes administering a bis-indole-derived compound to a subject in need thereof. In some embodiments, the method further includes binding, by the bis-indole-derived compound, to at least one of nuclear receptor 4A1 (NR4A1) and nuclear receptor 4A2 (NR4A2). In another embodiment, the present disclosure pertains to a compound for treating a disease by induction of activity in cells. Generally, the compound includes a bis-indole-derived compound. In some embodiments, the bis-indole-derived compound binds to at least one of NR4A1 and NR4A2.

Abstract: NR4A1 ligands, pharmaceutical compositions including the NR4A1 ligands, and related methods of use are described. Methods of treating a disease or condition in an individual treatable by modulation of NR4A1 activity, comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition described herein.

Abstract: The present disclosure provides compositions and methods for inhibiting ?1-integrin expression and functionality, and for addressing any condition characterized by increased ?1-integrin levels, through inhibition of NR4A1 (TR3) in the cell.

Abstract: Provided herein are methods directed to modulating the pro-oncogenic effects of noncoding RNAs (ncRNAs) through their interactions with specificity protein transcription factors (SpTFs). In one aspect, the disclosure provides a method of inhibiting growth of a cell, such as a transformed or cancer cell, characterized by overexpression of at least one specificity protein (Sp)-regulated ncRNA and expression of at least one Sp transcription factor (SpTF), the method comprising contacting the cell with an effective amount of an SpTF agent. In some embodiments, the ncRNA is a long noncoding RNA (lncRNA). In some embodiments, the ncRNA is a microRNA (miR). Also provided are methods of treating a cell proliferative disease, predicting the response of a subject to SpTF agent-based treatment, and monitoring the efficacy of a SpTF agent-based treatment in a subject.

Abstract: Presented herein are diindolylmethane derivative compounds useful for the prevention and or treatment of neurological conditions, including neurological conditions related to neuroinflammation. One such neurological condition is Parkinson's disease.

Abstract: Provided herein are methods directed to modulating the pro-oncogenic effects of noncoding RNAs (ncRNAs) through their interactions with specificity protein transcription factors (SpTFs). In one aspect, the disclosure provides a method of inhibiting growth of a cell, such as a transformed or cancer cell, characterized by overexpression of at least one specificity protein (Sp)-regulated ncRNA and expression of at least one Sp transcription factor (SpTF), the method comprising contacting the cell with an effective amount of an SpTF agent. In some embodiments, the ncRNA is a long noncoding RNA (lncRNA). In some embodiments, the ncRNA is a microRNA (miR). Also provided are methods of treating a cell proliferative disease, predicting the response of a subject to SpTF agent-based treatment, and monitoring the efficacy of a SpTF agent-based treatment in a subject.

Abstract: The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of NSAIDs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds can be used to inhibit cell growth, angiogenesis and metastasis in cancers such as pancreatic, breast, prostate, colon, bladder and ovarian cancers.

Abstract: The present invention provides a method for inducing ligand-dependant Nur77 activation in a cell by contacting the cell with an effective dose of an agonist of Nur77. Also provided is a method for treating a mammal having a disease affected by modulation of Nur77 activity as well as a method for inducing apoptosis in a cell. The Nur77 agonists are preferably diindolylmethanes, and more preferably, methlylene-substituted diindolylmethanes. A representative example of the Nur77 agonists is a 1,1-bis (3?-indolyl)-1-(p-substituted phenyl) methane.

Abstract: Diindolylmethane analogs such as 1,1-bis(3?-indolyl)-1-(p-substituted phenyl)methanes can be used to treat atherosclerosis and other vascular disease states. The analogs have been shown to display antiinflammatory effects in endothelial cells, suggesting their clinical applicability.

Abstract: The present invention is directed to a method of modulating a prostate neoplasm by administering an alkyl-substituted PCDF.